RPG Life Sciences Stock Screener | Share Price & Fundamental Analysis
RPGLIFE
Pharmaceuticals
Screen RPG Life Sciences share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹2310.70
▼
-1.80 (-0.08%)
Share Price BSE
₹2304.75
▼
-11.00 (-0.48%)
Market Cap
₹3,778.50 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
7.02
EPS (TTM)
₹110.80
Dividend Yield
1.02%
Debt to Equity
-
52W High
₹2657.80
52W Low
₹1969.50
Operating Margin
22.00%
Profit Margin
26.67%
Revenue (TTM)
₹806.00
EBITDA
₹288.00
Net Income
₹215.00
Total Assets
₹658.00
Total Equity
₹531.00
RPG Life Sciences Share Price History - Stock Screener Chart
Screen RPGLIFE historical share price movements with interactive charts. Analyze price trends and patterns.
RPG Life Sciences Company Profile - Fundamental Screener
Screen RPG Life Sciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for RPGLIFE shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE105J01010
RPG Life Sciences Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen RPGLIFE balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 658 | 513 | 419 | 345 | 303 | 267 | 251 | 291 | 247 | 205 |
| Current Assets | 465 | 298 | 264 | 207 | 176 | 126 | 97 | 143 | 96 | 87 |
| Fixed Assets | 172 | 114 | 124 | 104 | 113 | 123 | 128 | 131 | 137 | 109 |
| Liabilities | ||||||||||
| Total Liabilities | 658 | 513 | 419 | 345 | 303 | 267 | 251 | 291 | 247 | 205 |
| Current Liabilities | 7 | 7 | 9 | 9 | 7 | 8 | 13 | 16 | 21 | 5 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 531 | 375 | 308 | 256 | 216 | 177 | 161 | 155 | 147 | 134 |
| Share Capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
| Reserves & Surplus | 517 | 362 | 294 | 243 | 203 | 163 | 147 | 142 | 134 | 120 |
Screen RPGLIFE income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | None-None | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 806 | 666 | 589 | 518 | 443 | 390 | 376 | 331 | 345 | 294 | 280 | 243 |
| Expenses | 517 | 494 | 454 | 410 | 354 | 319 | 316 | 297 | 306 | 266 | 256 | 228 |
| EBITDA | 288 | 172 | 135 | 108 | 89 | 71 | 60 | 34 | 39 | 28 | 24 | 15 |
| Operating Profit % | 22.00% | 24.00% | 22.00% | 20.00% | 20.00% | 18.00% | 16.00% | 10.00% | 11.00% | 9.00% | 8.00% | 6.00% |
| Depreciation | 21 | 21 | 17 | 16 | 16 | 17 | 16 | 15 | 14 | 11 | 10 | 11 |
| Interest | 1 | 1 | 0 | 0 | 1 | 1 | 2 | 4 | 4 | 3 | 3 | 3 |
| Profit Before Tax | 267 | 233 | 118 | 92 | 73 | 54 | 37 | 15 | 20 | 15 | 12 | 1 |
| Tax | 50 | 50 | 30 | 24 | 22 | 14 | 7 | 4 | 7 | 3 | 0 | 0 |
| Net Profit | 215 | 183 | 88 | 68 | 52 | 40 | 29 | 11 | 14 | 12 | 12 | 1 |
| EPS | 130.30 | 110.80 | 53.01 | 40.90 | 31.13 | 24.19 | 17.54 | 6.54 | 8.13 | 12.70 | 7.03 | 0.60 |
RPG Life Sciences Cash Flow Screener - Liquidity Fundamentals
Screen RPGLIFE cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 78 | 94 | 91 | 65 | 58 | 50 | 46 | 15 | 7 | 33 |
| Investing Activities | -42 | -79 | -106 | -35 | -8 | -11 | -19 | -16 | -30 | -15 |
| Financing Activities | -27 | -20 | -17 | -14 | -11 | -39 | -27 | 0 | 23 | -18 |
| Net Cash Flow | 9 | -5 | -32 | 17 | 40 | 0 | 0 | -1 | 1 | 0 |
Screen RPGLIFE shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 72.95% | 72.95% | 72.95% | 72.81% | 72.81% | 72.81% | 72.95% | 72.81% |
| FII Holding | 1.45% | 1.35% | 1.11% | 0.89% | 1.14% | 1.35% | 1.30% | 0.00% |
| DII Holding | 6.14% | 6.48% | 6.70% | 4.19% | 4.63% | 5.45% | 6.06% | 2.12% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 15.33% | 15.46% | 15.37% | 17.41% | 16.79% | 15.92% | 15.58% | 19.91% |
| Other Holding | 4.12% | 3.76% | 3.88% | 4.70% | 4.62% | 4.47% | 4.11% | 5.16% |
| Shareholder Count | 24,867 | 25,832 | 26,657 | 22,137 | 22,232 | 23,481 | 24,891 | 20,837 |
RPG Life Sciences Dividend Screener - Share Yield Analysis
Screen RPGLIFE dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2025-March | ₹24.00 | 1.03% |
| 2024-March | ₹16.00 | 0.70% |
| 2023-March | ₹12.00 | 0.79% |
| 2022-March | ₹9.60 | 1.40% |
| 2021-March | ₹7.20 | 1.28% |
| 2020-March | ₹4.00 | 1.03% |
| 2019-March | ₹2.40 | 1.41% |
| 2018-March | ₹2.40 | 0.97% |
| 2017-March | ₹2.80 | 0.73% |
| 2016-March | ₹0.00 | 0.00% |
RPG Life Sciences Index Membership - Market Screener Classification
Screen RPGLIFE by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
RPG Life Sciences Market Events Screener - Corporate Actions
Screen RPGLIFE market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2025-10-17 | 2025-10-17 | Quarterly Result Announcement | NA | 1.67% |
| 2025-07-25 | 2025-07-25 | Quarterly Result Announcement | NA | -1.23% |
| 2025-07-16 | 2025-07-16 | Annual General Meeting | NA | 9.29% |
| 2025-06-27 | 2025-06-27 | Dividend | ₹ 20.00 /share | 8.23% |
| 2025-06-27 | 2025-06-27 | Dividend | ₹ 4.00 /share | 8.23% |
| 2025-04-28 | 2025-04-28 | Quarterly Result Announcement | NA | 1.90% |
| 2025-01-24 | 2025-01-24 | Quarterly Result Announcement | NA | 4.48% |
| 2024-11-07 | 2024-11-07 | Quarterly Result Announcement | NA | 9.58% |
| 2024-07-16 | 2024-07-16 | Annual General Meeting | NA | 6.61% |
| 2024-06-28 | 2024-06-28 | Dividend | ₹ 16.00 /share | 3.25% |
| 2023-07-21 | 2023-07-21 | Dividend | ₹ 12.00 /share | 21.72% |
| 2022-07-14 | 2022-07-15 | Dividend | ₹ 9.60 /share | -3.56% |
| 2021-08-13 | 2021-08-17 | Dividend | ₹ 7.20 /share | 5.36% |
RPG Life Sciences Competitors Screener - Peer Comparison
Screen RPGLIFE competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 412,734 | 39.30 | 54,729 | 9.71% | 10,980 | 39.06 |
| Divis Laboratories | 168,851 | 68.25 | 9,712 | 18.67% | 2,191 | 44.96 |
| Torrent Pharmaceuticals | 129,357 | 59.98 | 11,539 | 6.99% | 1,911 | 59.35 |
| Cipla | 120,557 | 22.21 | 28,410 | 7.12% | 5,291 | 42.76 |
| Dr Reddys Laboratories | 105,645 | 18.46 | 33,741 | 16.73% | 5,725 | 49.97 |
| Lupin | 95,023 | 21.85 | 22,910 | 13.74% | 3,306 | 50.10 |
| Zydus Life Science | 90,707 | 18.09 | 23,511 | 18.55% | 4,615 | 34.06 |
| Mankind Pharma | 88,846 | 50.78 | 12,744 | 20.90% | 2,007 | 40.67 |
| Aurobindo Pharma | 68,901 | 20.36 | 32,346 | 9.43% | 3,484 | 46.33 |
| Alkem Laboratories | 65,390 | 27.28 | 13,458 | 3.70% | 2,216 | 37.45 |
RPG Life Sciences Company Announcements - News Screener
Screen RPGLIFE latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-05 | Disclosure Under Regulation 30 Of SEBI LODR 2015 For Details Of Order Received From GST Authority Maharashtra | View |
| 2025-12-31 | Incorporation Of A Wholly Owned Subsidiary. | View |
| 2025-12-31 | Closure of Trading Window | View |
| 2025-12-15 | Disclosure Under Regulation 30(5) | View |
| 2025-12-15 | Intimation With Respect To Proposed Incorporation Of A Wholly Owned Subsidiary Is Enclosed Herewith | View |
| 2025-12-15 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-12-15 | Outcome Of The Board Meeting Held On December 15 2025 | View |
| 2025-11-28 | Disclosure Under Regulation 30 Of SEBI LODR 2015 For Details Of Order Received From GST Authority Gujarat. | View |
| 2025-11-15 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-10-24 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2025-10-18 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2025-10-18 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2025-10-18 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-10-17 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-10-17 | Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO) | View |
| 2025-10-17 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2025-10-17 | RPG Life Sciences Limited Has Submitted To The Exchange The Financial Results For The Quarter And Half Year Ended September 30 2025. | View |
| 2025-10-17 | Board Meeting Outcome for Outcome Of Board Meeting Held On October 17 2025 | View |
| 2025-10-14 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-10-13 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |